Literature DB >> 18385271

Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury.

Abdulla K Salahudeen1, Naeem Haider, John Jenkins, Manish Joshi, Harnish Patel, Hong Huang, Ming Yang, He Zhe.   

Abstract

Erythropoietin (Epo) induces erythrocytosis by suppressing erythroid progenitor cell apoptosis through the Janus-activated kinase-signal transducers and activators of transcription (JAK-STAT) pathway. Since apoptosis contributes to cisplatin (CP)-induced nephrotoxicity and Epo receptors (EpoR) are expressed in the kidney, we examined the role of antiapoptosis in recombinant human erythropoietin (rHuEpo)-mediated renal protection. In human renal proximal tubular epithelial (RPTE) cells in culture, rHuEpo, but not inactive rHuEpo (I-rHuEpo), the receptor-binding sites of which are mutated, caused a significant reduction in CP-induced apoptosis at > or = 100 U/ml. rHuEpo, but not I-rHuEpo, increased STAT5 and Akt/PKB phosphorylation, demonstrating functional EpoR expression on RPTE cells. Furthermore, the JAK2 inhibitor tyrphostin AG-490 attenuated rHuEpo protection, suggesting a role of the JAK-STAT pathway in rHuEpo-mediated antiapoptosis. In rats, intravenous administration of 5,000 U/kg rHuEpo, but not an equivalent peptide mass of I-rHuEpo, before a single 5.5 mg/kg iv injection of CP, significantly increased hematocrit (Hct) and reduced the CP-induced increase in serum creatinine. Serum creatinine on day 4 was 3.4 +/- 0.3, 1.9 +/- 0.3, and 3.5 +/- 0.4 mg/dl in the CP, CP + rHuEpo, and CP + I-rHuEpo groups, respectively. Similarly, darbepoietin-alpha (DA), a hyperglycosylated analog of rHuEpo with prolonged in vivo activity when injected at 25 microg/kg iv before CP, significantly increased Hct and reduced serum creatinine. Renal clearance studies based on glomerular filtration rate and renal blood flow confirmed the significant renal protection by DA against CP. Tubular apoptosis and necrosis were significantly reduced in the kidneys of the CP + DA vs. the CP + saline group. Moreover, the equalization of Hct by venesection did not abrogate the DA-mediated renal protection. Administration of DA 48 h after CP injection also conferred significant renal protection. Thus our experiments confirm a role for erythropoiesis-stimulating proteins, including the new analog DA, in limiting CP-induced nephrotoxicity and suggest that antiapoptosis via the Epo-EpoR interaction is an important mechanism for renal protection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385271     DOI: 10.1152/ajprenal.00131.2008

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  15 in total

1.  Fenoldopam preconditioning: role of heme oxygenase-1 in protecting human tubular cells and rodent kidneys against cold-hypoxic injury.

Authors:  Abdulla K Salahudeen; Ming Yang; Hong Huang; Sylvain Dore; David E Stec
Journal:  Transplantation       Date:  2011-01-27       Impact factor: 4.939

2.  Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial.

Authors:  Kalathil K Sureshkumar; Sabiha M Hussain; Tina Y Ko; Ngoc L Thai; Richard J Marcus
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-28       Impact factor: 8.237

3.  Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin.

Authors:  Hiroto Ueba; Michael Brines; Michael Yamin; Tomio Umemoto; Junya Ako; Shin-ichi Momomura; Anthony Cerami; Masanobu Kawakami
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

Review 4.  Bridging Translation by Improving Preclinical Study Design in AKI.

Authors:  Mark de Caestecker; Ben D Humphreys; Kathleen D Liu; William H Fissell; Jorge Cerda; Thomas D Nolin; David Askenazi; Girish Mour; Frank E Harrell; Nick Pullen; Mark D Okusa; Sarah Faubel
Journal:  J Am Soc Nephrol       Date:  2015-11-04       Impact factor: 10.121

5.  Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin.

Authors:  Hiroto Ueba; Masashi Shiomi; Michael Brines; Michael Yamin; Tsutomu Kobayashi; Junya Ako; Shin-Ichi Momomura; Anthony Cerami; Masanobu Kawakami
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

6.  Aged kidney: can we protect it? Autophagy, mitochondria and mechanisms of ischemic preconditioning.

Authors:  Stanislovas S Jankauskas; Denis N Silachev; Nadezda V Andrianova; Irina B Pevzner; Ljubava D Zorova; Vasily A Popkov; Egor Y Plotnikov; Dmitry B Zorov
Journal:  Cell Cycle       Date:  2018-07-25       Impact factor: 4.534

7.  Erythropoietin (EPO) in acute kidney injury.

Authors:  Elizabeth Moore; Rinaldo Bellomo
Journal:  Ann Intensive Care       Date:  2011-03-21       Impact factor: 6.925

8.  Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial.

Authors:  Adis Tasanarong; Soodkate Duangchana; Sangduen Sumransurp; Boonlawat Homvises; Opas Satdhabudha
Journal:  BMC Nephrol       Date:  2013-07-05       Impact factor: 2.388

Review 9.  STAT5 as a Key Protein of Erythropoietin Signalization.

Authors:  Zuzana Tóthová; Jana Tomc; Nataša Debeljak; Peter Solár
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

10.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.